THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER VACCINATION AGAINST COVID-19 – A CASE REPORT

YASH N PANCHAL; MAITRI M PATEL; MUKUNDKUMAR V PATEL

doi:10.22159/ajpcr.2022.v15i4.44241

Authors

YASH N PANCHAL Department of Pharmacology, AMC MET Medical College, Ahmedabad, Gujarat, India. https://orcid.org/0000-0003-4663-0705
MAITRI M PATEL Department of Internal Medicine, GCS Medical College, Hospital and Research Center, Ahmedabad, Gujarat, India. https://orcid.org/0000-0002-4845-5894
MUKUNDKUMAR V PATEL Department of Internal Medicine, Dr. Kiran C. Patel Medical College and Research Institute, Bharuch, Gujarat, India. https://orcid.org/0000-0003-3003-1265

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i4.44241

Keywords:

Thrombotic thrombocytopenic purpura, COVID-19, Vaccination, Covishield, Plasma exchange therapy

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare but fatal thrombotic microangiopathy. Circulating AntiADAMTS13 antibodies produced in response to various triggering events, such as vaccinations, autoimmune disorders, malignancy, and administration of several drugs lead to acquired TTP (aTTP). This case concerns a 26-year-old male with aTTP after receiving the second dose of the Covishield vaccine (Oxford-AstraZeneca COVID-19 vaccine, code-named AZD1222). He presented with bruises, petechia, fatigue, dyspnea, and arthralgia post-vaccination. Laboratory reports showed thrombocytopenia, hemolytic anemia, a significant ADAMTS13 deficiency, and a high level of autoantibody titer against ADAMTS13. We treated the patient with plasma exchange therapy and prednisolone, and after the treatment, he recovered.

Downloads

Download data is not yet available.

References

Kucukyurt S, Eskazan AE. Assessment and monitoring of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP): Strategies to improve outcomes. J Blood Med 2020;11:319-26. doi: 10.2147/JBM.S205630, PMID 33061729

Doevelaar AA, Bachmann M, Hölzer B, Seibert FS, Rohn BJ, Bauer F, et al. von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med 2021;49:e512-20. doi: 10.1097/CCM.0000000000004918, PMID 33591004

Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood 2019;133:1644-51. doi: 10.1182/ blood-2018-11-884700, PMID 30770395

Knöbl P. Thrombotic thrombocytopenic purpura. Memo 2018;11:220-6. doi: 10.1007/s12254-018-0429-6, PMID 30220931

Szóstek-Mioduchowska A, Kordowitzki P. Shedding light on the possible link between ADAMTS13 and vaccine-induced thrombotic thrombocytopenia. Cells 2021;10:2785. doi: 10.3390/cells10102785, PMID 3468576

Miesbach W, Menne J, Bommer M, Schönermarck U, Feldkamp T, Nitschke M, et al. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: A hospital level study. Orphanet J Rare Dis 2019;14:260. doi: 10.1186/s13023-019-1240-0, PMID 31730475

Althaus K, Marini I, Zlamal J, Pelzl L, Singh A, Häberle H, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood 2021;137:1061-71. doi: 10.1182/blood.2020008762, PMID 33512415

Yavaşoğlu İ. Vaccination and thrombotic thrombocytopenic purpura. Turk J Haematol 2020;37:218-9. doi: 10.4274/tjh. galenos.2020.2020.0060, PMID 32227797

Kirpalani A, Garabon J, Amos K, Patel S, Sharma AP, Ganesan SL, et al. Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab. Br J Haematol 2022;196:e11-4. doi: 10.1111/bjh.17782, PMID 3440540

Al-Ahmad M, Al-Rasheed M, Shalaby NA. Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca- Oxford COVID-19 vaccine. EJHaem 2021; 2:534-6. doi: 10.1002/ jha2.219, PMID 34226899

Yocum A, Simon EL. Thrombotic thrombocytopenic purpura after Ad26.COV2-S vaccination. Am J Emerg Med 2021;49:441.e3-4. doi: 10.1016/j.ajem.2021.05.001, PMID 33980419

Waqar SH, Khan AA, Memon S. Thrombotic thrombocytopenic purpura: A new menace after COVID bnt162b2 vaccine. Int J Hematol 2021;114:626-9. doi: 10.1007/s12185-021-03190-y, PMID 34264514

Maayan H, Kirgner I, Gutwein O, Herzog-Tzarfati K, Rahimi-Levene N, Koren-Michowitz M, et al. Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. J Thromb Haemost 2021;19:2314-7. doi: 10.1007/s12185-021-03190-y, PMID 34264514

Brodin-Sartorius A, Guebre-Egziabher F, Fouque D, Cozon G, Villar E, Laville M, et al. Recurrent idiopathic thrombotic thrombocytopenic purpura: A role for vaccination in disease relapse? Am J Kidney Dis 2006;48:e31-4. doi: 10.1053/j.ajkd.2006.04.090, PMID 16931205

de Bruijn S, Maes MB, De Waele L, Vanhoorelbeke K, Gadisseur A. First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost 2021;19:2014-8. doi: 10.1111/jth.15418, PMID 34105244

Pai M, Grill A, Ivers N, Maltsev A, Miller KJ, Razak F, et al. Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following Astra Zeneca COVID-19 vaccination. Science briefs of the Ontario covid-19 science advisory table 2021;1:10.

von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Targeting pathomechanisms with bruton tyrosine kinase inhibitors. Thromb Haemost 2021;121:1395-9. doi: 10.1055/a-1481-3039, PMID 33851389